Search results
Results from the WOW.Com Content Network
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. After all, it's been less than a year since regulators in the U.S. and E.U. approved its ...
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
For premium support please call: 800-290-4726 more ways to reach us
In June 2021, Intellia made history by announcing interim Phase 1 data for NTLA-2001, demonstrating the ability to precisely edit target cells within the body to treat genetic disease with a single intravenous infusion of CRISPR. This was the first time any human clinical data has been published for an in vivo gene editing therapeutic candidate.
The stock ticker for CRISPR Therapeutics; Clerics Regular of Saint Paul (Barnabites), a religious order in the Catholic Church; Center for Research in Security Prices at the University of Chicago; Colorado River Storage Project; Canadian Registered Safety Professional designation administered by the Board of Canadian Registered Safety Professionals
CRISPR Therapeutics (CRSP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day.